Research > Other lines

Other lines

Number of publications
558
Publications search

  • Diaz-Gomez, J; Twyman, RM; Zhu, CF; Farre, G; Serrano, JCE; Portero-Otin, M; Muñoz, P.; Sandmann, G; Capell, T; Christou, P

    Biofortification of crops with nutrients: factors affecting utilization and storage

    Current Opinion In Biotechnology 44 115-123. .

    [doi:10.1016/j.copbio.2016.12.002]

  • Colas-Meda, P; Viñas I; Oliveira, M; Anguera, M; Serrano, JCE; Abadias, M

    Exposure to minimally processed pear and melon during shelf life could modify the pathogenic potential of Listeria monocytogenes

    FOOD MICROBIOLOGY 62 275-281. .

    [doi:10.1016/j.fm.2016.10.016]

  • Domingo, P; Sancho, F

    Neisseria meningitidis and purpura fulminans in a woman with chronic liver disease

    LANCET INFECTIOUS DISEASES 17 459-459. .

    [doi:10.1016/S1473-3099(16)30191-8]

  • Senent, L.; Lorenzo, I.; Vicente, A.; Alonso, E.; Sanzo, C.; Ramos, F.; Arenillas, L.; Orero, M.; Navarro, B.; Marco, V.; Diez Campelo, M.; Jerez, A.; Montoro, J.; Arrizabalaga, B.; Bonanad, S.; Lluch, R.; Paz, R. D.; Font, P.; Gomis, F.; Sanz, G.

    PROGNOSTIC IMPLICATION OF THE PERCENTAGE OF ERYTHROID CELLS IN BONE MARROWAT DIAGNOSIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME

    LEUKEMIA RESEARCH 55 151-152. .

    [doi:10.1016/S0145-2126(17)30375-2]

  • Huerva, V; Traveset, AE; Vilardell, F

    Topical Interferon Alpha-2b for Diffuse Conjunctival Primary Acquired Melanosis with Atypia

    Ocular Immunology And Inflammation 25 284-286. .

    [doi:10.3109/09273948.2015.1115880]

  • Pifarre, M; Carrera, A; Vilaplana, J; Cuadrado, J; Solsona, S; Abella, F; Solsona, F; Alves, R

    TControl: A mobile app to follow up tobacco-quitting patients

    COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE 142 81-89. .

    [doi:10.1016/j.cmpb.2017.02.022]

  • Cabezon, M.; Bargay, J.; Xicoy, B.; Garcia, O.; Tormo, M.; Palomo, L.; Marce, S.; Valcarcel, D.; Pedro, C.; Jimenez, M. J.; Borras, J.; Guardia, R.; Brunet, S.; Marti, J. M.; Garcia, A.; Zamora, L.

    TP53 MUTATIONS IN HIGH RISK MYELODYSPLASTIC SYNDROMES PATIENTS TREATED WITH AZACITIDINE ACCORDING TO CETLAM GROUP PROTOCOL

    LEUKEMIA RESEARCH 55 155-155. .

    [doi:10.1016/S0145-2126(17)30383-1]

  • Redondo Guijo, A. M.; Sanchez-Barba, M.; Sanz Santillana, G.; Bernal, T.; Arnan Sangerman, M.; Ramos Ortega, F.; Pedro Olive, C.; Amigo Lozano, M. L.; Marco Betes, V.; Valcarcel, D.; Ardanaz, M.; Brunet, S.; Bargay Lleonart, J.; Tormo, M.; Xicoy, B.; Nomdedeu, M.; Lopez Cadenas, F.; Caballero Berrocal, J. C.; Canizo, M. C. D.; Diez-Campelo, M.

    WHAT IS THE OUTCOME OF PATIENTS IN THE INTERMEDIATE IPSS-R SCORE GROUP? SPANISH APPROACH FOR BETTER STRATIFICATION WITH CLASSICAL TOOLS

    LEUKEMIA RESEARCH 55 150-151. .

    [doi:10.1016/S0145-2126(17)30374-0]

  • Arroyo D; Betriu A; Valls J; Gorriz JL; Pallares V; Abajo M; Gracia M; Valdivielso JM; Fernandez E

    Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study

    NEPHROLOGY DIALYSIS TRANSPLANTATION 32 513-520. .

    [doi:10.1093/ndt/gfw039]

  • Saumoy, M; Tiraboschi, JM; Ordoñez-Llanos J; Ribera, E; Domingo, P; Mallolas, J; Curto, J; Gatell, JM; Podzamczer, D

    Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy

    HIV CLINICAL TRIALS 18 49-53. .

    [doi:10.1080/15284336.2016.1275425]

  • Negredo, E; Estrada, V; Domingo, P; Gutierrez, MD; Mateo, GM; Puig, J; Bonjoch, A; Ornelas, A; Echeverria, P; Estany, C; Toro, J; Clotet, B

    Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 72 844-849. .

    [doi:10.1093/jac/dkw504]

  • Gasol Cudos, A.; Morales Murillo, S.; Panades Siurana, M. J.; Vilardell Villellas, F.; Canosa Morales, C.; Mele Olive, J.; Iglesias Martinez, E.; Salud Salvia, A.

    Change in treatment decisions according to Oncotype Dx Recurrence Score in node positive and negative, estrogen-receptor positive (ER+), HER2 negative breast cancer in a single institution

    BREAST 32 92-93. .